23:24 , May 15, 2019 |  BC Extra  |  Company News

Management tracks: Biogen’s McKenzie departing for CSL; plus Rubius, SanBio, Avita and more

Paul McKenzie is leaving Biogen Inc. (NASDAQ:BIIB) as EVP, pharmaceutical operations & technology to become COO of CSL Ltd. (ASX:CSL). A veteran of Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb Co. (NYSE:BMY) and Merck & Co....
19:27 , Oct 9, 2018 |  BC Extra  |  Company News

Management tracks: Pfizer unveils Bourla’s team

Incoming Pfizer Inc. (NYSE:PFE) CEO Albert Bourla’s executive team will include a chief digital and technology officer and see Global President of Worldwide R&D and Medical Mikael Dolsten add the title of CMO. The new...
19:33 , Mar 31, 2017 |  BC Week In Review  |  Company News

Bionure Farma, Spiral Therapeutics deal

Bionure granted Spiral an option to acquire exclusive, worldwide rights to Bionure’s preclinical serum/glucocorticoid regulated kinase 2 (SGK2) agonists BN201 and BN119 to treat otolaryngology indications. Spiral plans to exercise the option by 3Q17. If...
08:00 , Dec 19, 2013 |  BC Innovations  |  Translation in Brief

Translational tidbits

Consorting with academia GlaxoSmithKline plc has set up an immuno-oncology consortium that invites academics from six cancer centers to view its nonpublic early pipeline programs and share ideas for new therapeutic candidates. The Oncology Clinical...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

Bionure, Myelin Repair Foundation deal

Bionure partnered with the foundation to evaluate the neuroprotective capabilities of Bionure's BN201 in promoting myelin repair for multiple sclerosis (MS) using the research tools and assays at the foundation's Translational Medicine Center. Bionure will...